Therese Standal
Background and activities
Research activity
Multiple myeloma is a cancer caused by accumulation of malignant plasma cells within the bone marrow. Almost all myeloma patients suffer from an osteolytic bone disease, caused by increased numbers of cells degrading bone (osteoclasts) and reduced numbers of cells producing bone (osteoblasts). Bone destruction is also common in inflammtory diseases such as rheumatoid arthritis.
My research focus is on how myeloma cells, myeloma derived factors and inflammation affects the activity and differentiation of osteoblast and osteoclasts. .
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
Journal publications
- (2019) N-glykosylering av serumproteiner endres ved myelomatose. Bestpractice Onkologi/Hematologi.
- (2019) Serum protein N-glycosylation changes in multiple myeloma. Biochimica et Biophysica Acta - General Subjects. vol. 1863 (5).
- (2018) BMP4 Gene Therapy Inhibits Myeloma Tumor Growth, but Has a Negative Impact on Bone. Blood. vol. 132.
- (2018) PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. OncoTarget. vol. 9 (62).
- (2018) Myelomatose - bein i ubalanse. Bestpractice Onkologi/Hematologi.
- (2018) Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes. Biomarker Research. vol. 6 (21).
- (2017) Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica. vol. 102 (7).
- (2017) Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Advances. vol. 27 (1).
- (2016) Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells. Immunity,Inflammation and Disease. vol. 4 (3).
- (2015) The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma. Immunity,Inflammation and Disease. vol. 3 (2).
- (2015) PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PLOS ONE. vol. 10:e0139867 (10).
- (2015) Osteogenic differentiation of human mesenchymal stem cells in mineralized alginate matrices. PLOS ONE. vol. 10 (3).
- (2014) The Primary Function of gp130 Signaling in Osteoblasts is to Maintain bone Formation and Strength, Rather than Promote Osteoclast Formation. Journal of Bone and Mineral Research. vol. 29 (6).
- (2014) Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer Journal. vol. 4.
- (2014) gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation. Journal of Endocrinology. vol. 223 (2).
- (2013) Dickkopf-1 is associated with periarticular bone loss in patients with rheumatoid arthritis. Open Journal of Rheumatology and Autoimmune Diseases.
- (2013) Anti-c-MET Nanobody® – a new potential drug in multiple myeloma treatment. European Journal of Haematology. vol. 91 (5).
- (2012) Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. vol. 26.
- (2012) Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. Journal of Bone and Mineral Metabolism. vol. 30 (1).
- (2012) Properties and cell compatibility of mineralized alginate hydrogel beads. European Cells and Materials. vol. 23.